FluoroPharma touts phase I tracer trial

Imaging agent developer FluoroPharma of Boston has received positive phase I clinical trial results for its myocardial perfusion imaging tracer, according to the company.

BFPET is a fluorine-18-labeled tracer designed to assess blood flow in the heart for the diagnosis of coronary artery disease. The phase I trial, led by principal investigator Dr. Alan Fischman at Massachusetts General Hospital in Boston, evaluated safety, distribution, and dosimetry of BFPET in 12 healthy subjects following a single-dose injection at rest.

The company hopes its development of cardiac agents will expand the use of PET beyond FDG and pave the way for cardiovascular PET, FluoroPharma said.

Related Reading

FluoroPharma licenses MGH PET agents, March 27, 2008

FluoroPharma begins MPI tracer trial, March 20, 2008

Boston Life Sciences ends FluoroPharma deal, July 27, 2005

Copyright © 2008 AuntMinnie.com

Page 1 of 436
Next Page